Literature DB >> 2906589

Metabolism of lovastatin by rat and human liver microsomes in vitro.

M D Greenspan1, J B Yudkovitz, A W Alberts, L S Argenbright, B H Arison, J L Smith.   

Abstract

The metabolism of lovastatin (Mevacor) was examined using isolated microsomes derived from the livers of normal and phenobarbital-treated rats and from human liver samples. Incubation of lovastatin with rat liver microsomes resulted in the formation of several polar metabolites of lovastatin. The metabolites were isolated by HPLC and identified by NMR and mass spectrometry. One fraction consisted of a 2:1 mixture of 6-hydroxy-lovastatin and the rearrangement product delta 4,5-3-hydroxy lovastatin. Addition of a trace of acid to this mixture resulted in the formation of a single aromatized product, the desacyl-delta 4a,6,8-dehydro analog of lovastatin. Another microsomal metabolite was determined to be the delta 4,8a,1-3-hydroxy-lovastatin derivative. The chromatographic pattern of metabolites produced from lovastatin by human liver microsomes was similar to that obtained with rat liver microsomes. Metabolism of lovastatin by rat liver microsomes was both time and concentration dependent; optimal microsomal metabolism occurred with 0.1 mM lovastatin, whereas higher lovastatin concentrations inhibited the reaction. The open acid form of lovastatin was poorly metabolized by both the rat and the human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906589

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects.

Authors:  Ophelia Qi Ping Yin; Valiant Wah Lun Mak; Miao Hu; Benny Siu Pong Fok; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-01-27       Impact factor: 2.953

2.  Bama miniature pigs (Sus scrofa domestica) as a model for drug evaluation for humans: comparison of in vitro metabolism and in vivo pharmacokinetics of lovastatin.

Authors:  Yu Liu; Ben-Hua Zeng; Hai-Tao Shang; Yan-Yan Cen; Hong Wei
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

3.  Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.

Authors:  Jennifer M P Woo; Zhuofeng Lin; Mohamad Navab; Casey Van Dyck; Yvette Trejo-Lopez; Krystal M T Woo; Hongyun Li; Lawrence W Castellani; Xuping Wang; Noriko Iikuni; Ornella J Rullo; Hui Wu; Antonio La Cava; Alan M Fogelman; Aldons J Lusis; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

4.  Metabolic fate of 2,2-dimethylbutyryl moiety of simvastatin in rats: identification of metabolites by gas chromatography/mass spectrometry.

Authors:  N Uchiyama; Y Kagami; Y Saito; S Abe; M Ohtawa; S Hata
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jul-Sep       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.